You are here

Sage online ordering services are currently unavailable due to network disruption. We are working to restore service as soon as possible. In the meantime, our books are still available widely via retailers and online. Currently we are only able to supply digital inspection copies. These can be requested via this site, or direct from Vitalsource and Kortext. If you need a print copy, please contact your local Academic Sales Consultant, who will be able to arrange to send this once our systems are back online.

If you need further assistance please visit our Contact us page for further information. Thank you for your patience and we apologise for the inconvenience.

Rare Tumors

eISSN: 20363613 | ISSN: 20363613 | Current volume: 15 | Current issue: 1 Frequency: Yearly

Rare Tumors is a peer-reviewed, open access journal, which focusses on the study, diagnosis and treatment of rare cancers. The journal covers the diagnosis, classification, and treatment of rare tumors and haematological malignancies for physicians and medical scientists interested in uncommon neoplasms. Please see the Aims and Scopes tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

 Why publish in Rare Tumors?

  • Listed on PubMed and freely available via PubMed Central
  • Indexed in the Directory of Open Access Journals (DOAJ) and in the Web of Science Emerging Citation Index (ESCI)
  • Rigorous peer review of your research
  • Multidisciplinary audience
  • Prompt online publication
  • High visibility for global exposure

Open access article processing charge (APC) information

The APC for this journal is currently 2000 USD.

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.

Submission information

Submit your manuscript today at

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.


Please direct any queries to

Rare Tumors is an open access, peer-reviewed international medical journal devoted entirely to the study, diagnosis, and treatment of rare cancers. The journal covers the diagnosis, classification, and treatment of rare tumors and hematological malignancies for physicians and medical scientists interested in uncommon neoplasms. The primary intent of the journal will be to publish clinically relevant information that will directly improve the care of patients with rare cancers. Basic science studies of interest to those treating rare malignancies will also be considered for publication when relevant. A special section of the journal is dedicated to Case Reports: we would like to invite clinicians and researchers to send us their reports.

Dian Wang Rush University Medical Center, Chicago, USA
Associate Editor
Parul Barry University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Brian Van Tine Washington University Med Ct, St Louis, MO, USA
Editorial Board
Ramon Andrade de Mello Department of Medical Oncology, Oncology Portuguese Institute of Porto Francisco Gentil, Porto, Portugal
Armando Bartolazzi Department of Pathology, St. Andrea University Hospital, Rome, Italy
Alan T. Blank Rush University Medical Center, Chicago, IL, USA
Beth Z. Clark UPMC Magee-Womens Hospital, Pittsburgh, PA USA
Giacomo Deiro University of Turin, Italy
Guy Eslick Harvard School of Public Health, MA, USA
Nicola Fazio Istituto Europeo di Oncologia, Milan, Italy
Thorvardur Halfdanarson Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Angela C. Hirbe Washington University School of Medicine, St. Louis, MO, USA
Sergio Huerta Dallas VA Medical Center Surgical Services, Dallas, Texas, USA
Thomas Kim Rush University Medical Center, Chicago, IL, USA
Sameera Kumar Fox Chase Cancer Center, Philadelphia, PA, USA
Yun Li University of California San Francisco, San Francisco, CA, USA
Diane Ling Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Simon Lo Department of Radiation Oncology, Case Western Reserve University, UH Seidman Cancer Center, Cleveland, OH, USA
Oliver Micke Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Bielefeld, Germany
Timothy A.O. Oluwasola College of Medicine, University of Ibadan, Ibadan, Nigeria
Ken Tatebe Rush University Medical Center, Chicago, IL, USA
Jonathan C. Trent The University of Texas MD Anderson Cancer Center, TX, USA
Mark Gerard Trombetta Department of Radiation Oncology, West Penn Allegheny Health System Allegheny General Hospital, PA, USA
Meng Welliver Comprehensive Cancer Center, The Ohio State University, USA
Breelyn Wilky University of Colorado, Anschutz Medical Center, Aurora, CO, USA
Editorial Review Board
Mohammad-Salar Hosseini, MD, MPH Tabriz University of Medical Sciences, Tabriz, Iran
  • Clarivate Analytics: Emerging Sources Citation Index (ESCI)
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed Central (PMC)
  • Scopus

Manuscript submission guidelines can be accessed on Sage Journals.